Holen Sie sich die Stockscreener-App
14.36
0.28%
-0.04
Handel nachbörslich:
14.37
0.010
+0.07%
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize
Anika Therapeutics debuts Integrity and highlights portfolio at AAOS, Anika Therapeutics asserts - Traders Union
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal ConferenceSlideshow - Seeking Alpha
ANIK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) sharpens HA strategy with asset sales - Stock Titan
Does Anika Therapeutics, Inc. (ANIK) Have Momentum? - AAII
ANIK | Anika Therapeutics Inc FinancialsIncome Statement - Quiver Quantitative
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results - MarketBeat
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock - MarketBeat
ANIK: Barrington Research Raises Price Target to $17, Maintains 'Outperform' | ANIK Stock News - GuruFocus
Anika Therapeutics showcases Integrity benefits at ACFAS conference - Traders Union
Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating - marketscreener.com
B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating - marketscreener.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-02-27 - Seeking Alpha
Anika Therapeutics Q4 Profit Challenges Narratives Around Ongoing Losses For ANIK Investors - Sahm
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: - GuruFocus
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations - MSN
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations - Investing.com
Anika Therapeutics (ANIK) Reports Consistent Q4 Revenue with Pro - GuruFocus
Anika Therapeutics Q4 Earnings Call Highlights - MarketBeat
Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
ANIKA THERAPEUTICS ($ANIK) Releases Q4 2025 Earnings - Quiver Quantitative
Anika Announces Executive Transition Amid Stable Quarterly Results - TipRanks
Anika: Overview of Fourth Quarter Financial Results - Bitget
Anika: Q4 Earnings Snapshot - marketscreener.com
Anika Therapeutics extends transition agreement with Paul Colleran as EVP, General Counsel - TradingView
Anika (NASDAQ: ANIK) lifts margins as 2025 loss narrows sharply - Stock Titan
BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million - TradingView
Osteoarthritis treatments and cost cuts: Anika’s 2026 profit plan - Stock Titan
ANIK Should I Buy - Intellectia AI
Anika Therapeutics cites 40 publications and 16 years of clinical data for Hyalofast cartilage repair - Traders Union
Trading the Move, Not the Narrative: (ANIK) Edition - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference - The Manila Times
Live webcast: Anika CEO speaking at Canaccord musculoskeletal event - Stock Titan
Will Anika Therapeutics Inc. stock recover faster than peersJuly 2025 Levels & Reliable Intraday Trade Plans - mfd.ru
How Anika Therapeutics Inc. stock reacts to Fed rate cuts2025 Year in Review & Free AI Powered Buy and Sell Recommendations - mfd.ru
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 - ChartMill
Published on: 2026-02-13 12:04:47 - baoquankhu1.vn
Anika schedules Feb. 26 call on 2025 financial results - Stock Titan
(ANIK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Published on: 2026-02-11 15:28:04 - mfd.ru
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Lumicell Appoints Cheryl R. Blanchard to board - Medical Buyer
Positive week for Anika Therapeutics, Inc. (NASDAQ:ANIK) institutional investors who lost 41% over the past year - simplywall.st
Lumicell Appoints Cheryl R. Blanchard, Ph.D., To Board - citybiz
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors - ChartMill
Cancer imaging firm Lumicell taps 30-year biotech veteran Cheryl Blanchard for board - Stock Titan
Anika Therapeutics Inc. (NASDAQ:ANIK) Short Interest Update - MarketBeat
Anika Therapeutics Inc. $ANIK Shares Acquired by Capital Management Corp VA - MarketBeat
Price-Driven Insight from (ANIK) for Rule-Based Strategy - Stock Traders Daily
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc. - ACCESS Newswire
United States Joint Pain Injection Market to hit US$ 4.05 Billion - openPR.com
Anika Therapeutics Faces Investor Lawsuit Over Securities Violations - Intellectia AI
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewswire Inc.
Anika Therapeutics Shares Plunge 27% After Clinical Trial Fails to Meet Primary Endpoints - Intellectia AI
0.21%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):